Pre- and postcapillary pulmonary hypertension in dogs: Circulating biomarkers

被引:4
|
作者
Oleynikov, Dmitrij Arkadievich [1 ]
Yi, Ma [2 ]
机构
[1] Vet Clin Belij Klyk, Moscow, Russia
[2] Nacl Med Issledovatelskij Ctr Imeni VA Almazova S, St Petersburg, Russia
关键词
Biomarkers; Endothelin-1; Pulmonary hypertension; Serotonin; VEGF-D; ENDOTHELIAL GROWTH-FACTOR; HEART-FAILURE; HEALTHY DOGS; VEGF-D; SEROTONIN; PLASMA; BOSENTAN; EXTENT;
D O I
10.5455/OVJ.2022.v12.i4.8
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background: Pulmonary hypertension (PH) in dogs is a syndrome that could be primary or secondary due to pulmonary disease, pulmonary thromboembolism, heartworm disease, and heart failure. Due to the inability of right heart catheterization in veterinary patients, there is a lack of differential criteria between PH forms. In some acute cases. it is impossible to provide a full EchoCG or catheterization study. In this situation, circulating markers may be useful to discover the possible mechanism of PH form and provide specific therapy. Aim: Following all previous data in human and veterinary studies, we asstunal that plasm concentration of serotonin, endothelin-1 (ET-1), and vascular endothelial growth factor D (VEGF-D) would show a predominance in affected part of pulmonary circulation. Methods: We studied 59 small-breed dogs of different sexes and ages. Groups were formed according to a primary pathology: healthy dogs (n = 8); dogs with myxomatous mitral valve disease (MMVD) and postcapillary PH (PostPH, n = 23); dogs with MMVD and precapillaty PH (PrePH, n = 28). Animals in the study were diagnosed with the primary disease by standard echocardiographic methods and algorithms. Blood samples were collected at the moment of presentation and frozen in a -80 degrees C fridge. For biochemistry analysis, we used species-specific EL1SA kits, provided by Cloud-Clone Corp. (USA). The tests were provided by the means of Almazov National Medical Research Center, IEM laboratory. Results: Dogs with EchoCG-proved PostPH had a higher concentration of VEGF-D in comparison to control and PrePH (p <0.001, for both). There was no difference between the control and PrePH groups (p >0.05). ET-1 was higher in PrePH in comparison to PostPH and control dogs (p <0.001, for both). In addition, there was no difference between the control and PostPH groups (p >0.05). Serotonin concertation did not have a difference between controls and PostPH. However, it was higher in PrePH than in control (p <0.033) and PostPH group (p <0.006). Receiver operating curve analysis showed that plasma concentrations of ET-1 (0.99) and VEGF-D (0.92) had high effectiveness in the differentiation of PostPH and PrePH. Conclusion: This study showed a correlation between circulating biomarkers (serotonin. ET-1. and VEGF-D). We found a connection between ET-1 and right-sided heart failure as well as VEGF-D and left heart failure in the PH context.
引用
收藏
页码:469 / 480
页数:12
相关论文
共 50 条
  • [21] Predictors of a precapillary component in patients with postcapillary pulmonary hypertension
    Fard, Damien
    Boucly, Athenais
    Preda, Mariana
    Montani, David
    Jais, Xavier
    Savale, Laurent
    Mignard, Xavier
    Jevnikar, Mitja
    Jutant, Etienne-Marie
    Seferian, Andrei
    Humbert, Marc
    Vachiery, Jean-Luc
    Sitbon, Olivier
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [22] Alterations of pulmonary vascular afterload in exercise-induced pre- and post-capillary pulmonary hypertension
    Karvasarski, Elizabeth
    Bentley, Robert F.
    Buchan, Tayler A.
    Valle, Felipe H.
    Wright, Stephen P.
    Chang, Isaac S.
    Granton, John T.
    Mak, Susanna
    PHYSIOLOGICAL REPORTS, 2023, 11 (01):
  • [23] Circulating biomarkers in pulmonary arterial hypertension: Update and future direction
    Pezzuto, Beatrice
    Badagliacca, Roberto
    Poscia, Roberto
    Ghio, Stefano
    D'Alto, Michele
    Vitulo, Patrizio
    Mule, Massimilano
    Albera, Carlo
    Volterrani, Maurizio
    Fedele, Francesco
    Vizza, Carmine Dario
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (03) : 282 - 305
  • [24] First Global Assessment of Circulating Plasma MicroRNAs as Potential Biomarkers for Pulmonary Arterial Hypertension
    Schlosser, Kenny
    White, R. J.
    Stewart, Duncan J.
    CIRCULATION, 2012, 126 (21)
  • [25] Treatment-related biomarkers in pulmonary hypertension patients on oral therapies
    Swaminathan, Aparna C.
    Zhu, Hongmei
    Tapson, Victor
    Lokhnygina, Yuliya
    Poms, Abby
    Kelleher, Zach
    Gaspard, Elijah
    Kennedy, Karla
    Fee, Brian E.
    Fortin, Terry
    Mason, S. Nicholas
    Parikh, Kishan
    McMahon, Tim J.
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [26] Biomarkers in Pulmonary Arterial Hypertension
    Rosenthal J.L.
    Jacob M.S.
    Current Heart Failure Reports, 2014, 11 (4) : 477 - 484
  • [27] Biomarkers in Pulmonary Arterial Hypertension
    Hojda, Silvana Elena
    Chis, Irina Camelia
    Clichici, Simona
    DIAGNOSTICS, 2022, 12 (12)
  • [28] Biomarkers in pulmonary arterial hypertension
    Rafeq, S.
    Shah, A. M.
    Preston, I. R.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 : 36 - 41
  • [29] Screening for biomarkers in pulmonary hypertension
    Tiede, Svenja Lena
    Pullamsetti, Soni Savai
    Sydykov, Akylbek
    Lochnit, Guenter
    Tiede, Henning
    Ghofrani, Hossein Ardeschir
    Weissmann, Norbert
    Grimminger, Friedrich
    Seeger, Werner
    Schermuly, Ralph Theo
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [30] Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study
    Belyavskiy, Evgeny
    Ovchinnikov, Artem
    Potekhina, Alexandra
    Ageev, Fail
    Edelmann, Frank
    BMC CARDIOVASCULAR DISORDERS, 2020, 20 (01)